NCT07812467: Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
- State
- Not started
- Phase
- Phase 2
- People
- 220 planned
- Started
- 1 Oct 2026
- Primary completion
- 31 Oct 2028
- Arms
- Safety Run-In Combination Arm, Randomized Combination Arm
- Results
- None posted
- 10 Sep 2026: Trial registered